MPO and metabolic syndrome: Moderate dyslipidemia and dyslipoproteinemia have been reported to elevate inflammatory markers such as TNF-α and IL-6 concentrations, and inflammation slowly induces an increase in myeloperoxidase concentration, which decreases APOAI and HDL-C levels and disturbs HDL function, which confirms that inflammation plays an important role in dyslipidemia [19].